Clinical trial PEARLS
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
Cancers | |
---|---|
Organ | NSCLC |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Merck |
EudraCT Identifier | 2015-000575-27 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02504372 |
Inclusion criteria | Adjuvant. ECOG 0 or 1 |
Last update |